Teva and Sanofi’s Duvakitug Shows Sustained Efficacy in IBD Phase 2b Trial

  • Teva and Sanofi’s duvakitug maintained high rates of clinical remission and endoscopic improvement in ulcerative colitis (UC) and Crohn’s disease (CD) patients at Week 44 of the RELIEVE UCCD phase 2b long-term extension study.
  • Duvakitug demonstrated a dose response, with numerically higher efficacy outcomes at the 900 mg dose compared to the 450 mg dose in both UC and CD.
  • The drug was well tolerated, with a safety profile consistent with the induction phase and no new safety concerns identified.
  • Biomarker analyses showed duvakitug reduced markers of inflammation and tissue remodeling in both UC and CD.
  • Teva and Sanofi have initiated phase 3 studies for duvakitug in UC and CD, and a phase 2 study in hidradenitis suppurativa.

Teva and Sanofi’s positive phase 2b data for duvakitug underscores the potential of TL1A inhibition as a new treatment option for inflammatory bowel disease. The sustained efficacy and safety profile of duvakitug could position it as a competitive alternative in a market with significant unmet needs. The ongoing phase 3 studies will be critical in determining the drug’s future commercial potential.

Regulatory Approval
Whether duvakitug will receive regulatory approval based on the phase 3 study results.
Market Competition
How duvakitug will compete with existing therapies for UC and CD in the market.
Commercialization Strategy
The effectiveness of Teva and Sanofi’s co-commercialization strategy for duvakitug in different regions.